Preclinical models of negative symptoms and their implications for clinical trials. Martien Kas
|
|
- Edward Davis
- 6 years ago
- Views:
Transcription
1 Preclinical models of negative symptoms and their implications for clinical trials Martien Kas
2 From diagnose to biology ISCTM ~ ECNP Joint Conference 1 September 2017 Paris France
3 The road to restoring neuronal circuits Canter et al., Nature, 2016
4 The puzzle of schizophrenia stahlonline.cambridge.org
5 Integrated experimental approaches Dolmetsch and Geschwind, Cell, 2011
6 How to provide cross-species clinically relevant and quantitative endpoint measures?
7 Behavioural domains across the neuropsychiatric spectrum Kas et al., Molecular Psychiatry, 2007
8 Behavioural domains: negative symptoms Modeling positive versus negative symptoms in animals
9 Social withdrawal is a common (early) symptom across neuropsychiatric disorders Autism Spectrum Disorder Schizophrenia Social withdrawal Alzheimer s Disease Bipolar Depression Major Depression
10 Social withdrawal is influenced by several processes Social perception Social learning Cognitive performance Social information processing Social withdrawal Mentalizing activities Emotionality Reward processing
11 Social withdrawal is influenced by several processes Social perception Social learning Cognitive performance Social information processing Social withdrawal Mentalizing activities Emotionality Reward processing
12 The dopamine hypothesis Brunelin et al., 2013
13
14 Rodent models to alter dopamine signalling Striatal D 2 R overexpression mouse model Amphetamine model Dopamine transporter knock-out mice Neonatal ventral hippocampal lesion Isolation rearing
15 Recombinant technologies to delete or overexpress the Dopamine-2 receptor in mice Drew et al. J. Neuroscience, 2007
16 Reward processing: testing motivation
17 Performance in the progressive ratio task Drew et al. J. Neuroscience, 2007
18 Evolutionary conserved biological processes?
19 Social withdrawal is influenced by several processes Social perception Social learning Cognitive performance Social information processing Social withdrawal Mentalizing activities Emotionality Reward processing
20 Social information processing
21 duration (s) Social recognition minutes 24 hours
22 Mapping a locus on mouse chromosome 14 for long-term social recognition Mapping a locus on mouse chromosome 14 for social recognition Bruining et al., Biological Psychiatry, 2015
23 Pcdh9: associated to social behavioural deficits in human and dogs
24 Pcdh9-deficient mice: impaired social recognition Bruining et al. Biol. Psychiatry, 2015
25 Sensory processing deficits in Pcdh9 KO mice Touch evoked biting response Sensorimotor performance Prepulse inhibition
26 Cortical thinning of sensory cortex, and local dendritic and spine malformations Bruining et al., Biological Psychiatry, 2015
27 Mouse and human Sensory information processing Genetic variations Cortical integrity
28 From genetic variation to behavioural output Temporal & Spatial Synaptic density
29 Coupling sensory processing to neural biomarkers integrated EEG behavioural analyses
30 Sensory deficits: auditory mismatch negativity
31 Disease diversity
32 Precision medicine Insel and Cuthbert, Science, 2015
33 PRISM: Psychiatric Ratings using Intermediate Stratified Markers Project coordinator: Martien Kas, University of Groningen, the Netherlands Project leader: Hugh Marston, Eli Lilly and Company, United Kingdom The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
34 PRISM s general concept: Providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in Alzheimer s disease, schizophrenia and depression The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
35 23 partners, including major EU Academic Centres, SME s and pharmaceutical industry The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
36 Human and rodent homologies The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
37
38 Longitudinal and objective measures of rodent and human social withdrawal The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
39 BeHapp passive remote behavioural monitoring The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
40 Collected Data smartphone app MMS messages GPS location SMS messages Outgoing calls Returned calls Bluetooth signals in the area WiFi signals Incoming calls Application activity, such as: Missed calls Twitter events The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
41 Smartphone passive behavioural monitoring Movement trajectory extraction The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
42 Longitudinal and objective measures of rodent and human social withdrawal The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
43 Mimicking natural burrowing behaviour The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
44 Visible Burrow System: studying social interaction in a semi-natural environment The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
45 BTBR: Reduced social interaction and huddling The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
46 Summary Improving treatment efficacy in schizophrenia will benefit from advancing our knowledge on target neural circuitries and representative core readout. Understanding clinical heterogeneity requires the development and application of quantitative biological parameters that can be applied across the diagnostic boundaries. Implementation of homologous clinical and preclinical testing paradigms to assess quantitative biological parameters allow for the development of preclinical model systems to back-translate human findings and further expand our neurobiological knowledge. The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
47 VIDI-grant The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation programme and EFPIA.
Innovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
More informationOpen Innovation in action: IMI flagship projects PRISM and RADAR-AD
Brussels, October 18, 2017 Open Innovation in action: IMI flagship projects PRISM and RADAR-AD Emilio Merlo Pich, MD Head, Quantitative Medicine, CNS TAU, Takeda Pharmaceutical International, Zurich, CH
More informationSilver Linings Playbook: The Positive Side of Negative Trials ISCTM 13th Annual Scientific Meeting February 2017
Silver Linings Playbook: The Positive Side of Negative Trials ISCTM 13th Annual Scientific Meeting 21-23 February 2017 Steven J. Romano, MD Past President, ISCTM and EVP, Chief Science Officer, Mallinckrodt
More informationQPS Neuropharmacology Overview
HISTOCHEMISTRY HISTOLOGY KO MODELS IN VIVO MODELS BLOOD BRAIN BARRIER IN VITRO MODELS NEUROPHARMACOLOGY OVERVIEW NEUROSCIENCES QPS Neuropharmacology Overview QPS is recognized all over the world as a leading
More informationNeurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
More informationWebinar IMI2 - Call 9 Data quality in preclinical research and development. Thomas Steckler IMI webinar
Webinar IMI2 - Call 9 Data quality in preclinical research and development Thomas Steckler 11.04.2016 IMI webinar Need for public-private collaboration Low quality data hamper innovation and progress in
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationhttps://us12.admin.mailchimp.com/campaigns/preview-content-html?id=500409
Page 1 of 5 Message from the Director: Over the past two weeks, we have seen a lot of activity among the PIIN membership. I would like to thank everyone who was involved with our Traumatic Brain Injury
More informationDecision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers
Decision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers Kalpana Merchant, PhD Chief Scientific Officer, Tailored Therapeutics - Neuroscience Eli
More informationClinical studies. BARBORA VLKOVÁ INSTITUTE OF MOLECULAR BIOMEDICINE
Clinical studies BARBORA VLKOVÁ INSTITUTE OF MOLECULAR BIOMEDICINE www.imbm.sk barboravlk@gmail.com Biomedical research 1. Basic research a. In vitro = cell cultures b. In vivo = experimental animals c.
More informationNIMH Updates and Research Priorities
NIMH Updates and Research Priorities ASCP Annual Meeting May 31, 2018 Shelli Avenevoli, Ph.D. Disclosure of Affiliations No conflicts of interest or disclosures 2 Agenda NIH and NIMH Updates NIMH Intervention
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationANIMAL BEHAVIOR CORE - We need your input!!!
Page 1 of 5 Message from the Director April tends to be a busy month for all; students and faculty are preparing for the end of the semester. The Integrative Neuroscience Center Leadership Team has started
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationNEUROLOGY AND OPHTHALMOLOGY
NEUROLOGY AND OPHTHALMOLOGY OPPORTUNITIES AT INSERM BD & L: Anne Cochi anne.cochi@inserm-transfert.fr September 2017 1 WE PROPOSE A SELECTION OF PROJECTS AT DIFFERENT STAGES 4 Neurodegeneration patents
More informationThe Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationSteven J. Romano, MD Senior Vice President Medicines Development, Pfizer
A Return to Rational CNS Drug Development: De-risking P3 Investments through Rigorous Early Phase Drug Evaluation ISCTM Autumn Scientific Meeting, October 1, 2013 Steven J. Romano, MD Senior Vice President
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationInnovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
More informationAlberto Del Guerra Dipartimento di Fisica E. Fermi Università di Pisa, Italy
HORIZON 2020 IL NUOVO FRAMEWORK IN RICERCA E INNOVAZIONE Università di Pisa, 15 novembre 2013 Aula Magna Polo Fibonacci Largo Pontecorvo 3 Alberto Del Guerra Dipartimento di Fisica E. Fermi Università
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationNovel Methods leading to New Medications in Depression and Schizophrenia. Tine Bryan Stensbøl, Lundbeck coordinator of NEWMEDS
Novel Methods leading to New Medications in Depression and Schizophrenia Tine Bryan Stensbøl, Lundbeck coordinator of NEWMEDS Stakeholder meeting, Brussels June 14th 2010 NEWMEDS the work leading to these
More informationAD/PD Conference, Nice, Fr, 2015
AD/PD Conference, Nice, Fr, 2015 Overview, novelties and conclusions for domestic research NAP B MTA TTK MS Neuroproteomics Group Overlaping molecular mechanisms of miss-folded protein based neurodegenerative
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationPARTNERING IN NEUROSCIENCE Sharing a Vision to Help Improve Patients Lives
PARTNERING IN NEUROSCIENCE Sharing a Vision to Help Improve Patients Lives VISIT OUR WEBSITE FOR MORE INFORMATION: www.janssen.com/neuroscience MAY 2017 Johnson & Johnson Innovation LLC 2017. A Message
More informationCL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in
CL1 : Molecular imaging for diagnosis and treatment of neurodegenerative disorders at a prodromal stage CL2 : The role of non-coding RNAs in malignant cardiac diseases CL3 : Large scale optical imaging
More informationHandy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
The Center for Neural Development and Disease (will be The Center for NeuroTherapeutics Discovery) Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationPsych 3102 Introduction to Behavior genetics. Lecture 13 Identifying genes for behavioral traits
Psych 3102 Introduction to Behavior genetics Lecture 13 Identifying genes for behavioral traits - towards behavioral genomics QUANTITATIVE GENETICS biometrical methods natural genetic variation complex
More informationBiogen Idec and Collaborative Brain Research. Dominic Paes PhD EU Medical Sciences, Neurology Zug, Switzerland
Biogen Idec and Collaborative Brain Research Dominic Paes PhD EU Medical Sciences, Neurology Zug, Switzerland AREAS OF HIGH UNMET MEDICAL NEED NEUROLOGY IMMUNOLOGY HEMATOLOGY MS - Repair / Progressive
More informationPage 1 of 5 Message from the Director: As the summer kicks off, many of us will renew our focus on research and scholarship. Towards this goal, we draw your attention to a several upcoming events and opportunities
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationTeacher Genes for Memory
1 Lesson Overview Students learn about the connections between genes and cognition by experimenting with knockout mice. By interacting with the animated experiments and interpreting results, students draw
More information1: Executive Summary The Brain Industry Revealed Neuropharmaceuticals Cell Therapies Neurodevices Neurodiagnostics Investment Risks and Opportunities
1: Executive Summary The Brain Industry Revealed Neuropharmaceuticals Cell Therapies Neurodevices Neurodiagnostics Investment Risks and Opportunities Translating Neuroscience into Neurotech The Neurotech
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationOMICS Journals are welcoming Submissions
OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible
More informationInitiatives to Support Research Activities for Translational Challenges in Neurology
Initiatives to Support Research Activities for Translational Challenges in Neurology ASCP Annual Meeting June 1, 2017 Amir P. Tamiz, Ph.D. Associate Director, National Institute of Neurological Disorders
More informationInnovative Medicines Initiative:
Innovative Medicines Initiative: Opportunities for local players to become important parts of multicountry pharma innovation Nathalie Serigneuret 4 March 2015 Clinical Trials Conference 2015, Budapest
More informationIMI: A Public Private Partnership Funder
IMI: A Public Private Partnership Funder 25-26 July 2011, European Medicines Agency Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy The Innovative Medicines Initiative (IMI):
More informationData Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs. Critical Path Institute s Alzheimers Drug Development Tool
Data Sharing and Models in Pre(Non)- Competitive Space in Addressing Unmet Medical Needs Critical Path Institute s Alzheimers Drug Development Tool Vikram Sinha, PhD Director, Division of Pharmacometrics
More informationPharmaCog Alzheimer s Disease
PharmaCog Alzheimer s Disease Esther Schenker Institut de Recherches Servier France The issue People with dementia Total costs Billions US$ Western Europe 210.12 Central Europe 14.19 Eastern Europe 14.33
More informationRisperidone and NAP protect cognition and normalize gene expression in a schizophrenia. mouse model
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model Short title: Risperidone and NAP protect Foxp2 in DISC1 mice Sinaya Vaisburd 1, Zeev Shemer 1, Adva Yeheskel
More informationNINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain
NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain OCTOBER 30, 2018 Mary Ann Pelleymounter, PhD Program Director mary.pelleymounter@nih.gov 1 About the Speaker
More informationLinda Crnic Institute for Down Syndrome Seed Grant Proposals
Linda Crnic Institute for Down Syndrome Seed Grant Proposals Grant Application Information INTRODUCTION The Linda Crnic Institute for Down Syndrome is a part of the University of Colorado, housed on both
More informationBioXplain The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology
The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology BioXplain 2009 Pharma R&D critical challenge Despite increasing investments in Technology
More informationBioMolecular Imaging, LLC
BioMolecular Imaging, LLC Bridging the Preclinical - Clinical Divide in Translational Imaging: The Push, Pull and Pitfalls J. James Frost, MD, PhD, MBA JamesFrost@BioMolecularImaging.com Introduction The
More informationPrinciples of translational medicine: imaging, biomarker imaging, theranostics
Principles of translational medicine: imaging, biomarker imaging, theranostics Compiled by: Endre Mikus PhD, CEO Budapest, 21/9/2015 Imaging and imaging biomarkers An imaging biomarker is an anatomic,
More informationGenes & Medicine: How DNA is Improving Your Health
Genes & Medicine: How DNA is Improving Your Health U3A Mountford, June 2004 Dr Martin Kennedy Department of Pathology Christchurch School of Medicine & Health Sciences University of Otago What this talk
More informationPartnering in Neuroscience Sharing a Vision to Help Improve Patients Lives. Janssen Research & Development, LLC
Partnering in Neuroscience Sharing a Vision to Help Improve Patients Lives Janssen Research & Development, LLC 2 Yvonne Ford, Untitled Artwork Artwork from Reflections Art in Health, a user-led charity
More informationComparative Oncology Program
The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative
More informationWhen should non human primates be used as animal models?
When should non human primates be used as animal models? Roger Lemon Sobell Department of Motor Neuroscience and Movement Disorders UCL Institute of Neurology Queen Square Animal Research Regulation Meeting
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationCoordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
More informationForthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationgraduate programme 2018
graduate programme 2018 2 lundbeck graduate programme lundbeck graduate programme 3 the programme Starting this September, you can become part of Lundbeck s Graduate Programme. JOIN THE GRADUATE JOURNEY
More informationNEWSLETTER. April
NEWSLETTER April 2018 www.nyrada.com Since the initial newsletter was posted in January, Nyrada has been busy transitioning into a fully functioning company with new staff joining and the development program
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationAn alternative path to commercial imaging agent viability companion imaging diagnostics. Adrian Nunn
An alternative path to commercial imaging agent viability companion imaging diagnostics. Adrian Nunn Adrian.nunn@bru.bracco.com 1 The three generic proofs for any drug adapted for molecular imaging (MI)
More informationConsiderations on regulatory aspects
Considerations on regulatory aspects Regulatory framework for medicinal products in the context of therapeutic use of bacteriophages EMA Workshop on 8 June Presented by Zigmars Sebris on 8 June 2015 Regulatory
More informationIntroduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationNon-Dilutive Funding for Opportunities for CNS/PNS Related R&D
FreeMindGroup FreeMind Group @FreeMindGrp Non-Dilutive Funding for Opportunities for CNS/PNS Related R&D Jonathan H. Adalist Sr. Director, Business Development September 6, 2017 FreeMind Group FreeMind
More informationMagneto: remote control over neuronal activity and behaviour. Yvette Zarb Division of Neurosurgery
Magneto: remote control over neuronal activity and behaviour Yvette Zarb Division of Neurosurgery Gene expression Studying the actions specific cells and gene products is essential in understanding their
More informationFDA from a Former FDAer: Secrets and insights into regulatory review and drug development
FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA
More informationTOP ST. search articles. ' s. . Discovery brings with it possible implications for brain regeneration -
Like 1.1M Follow 0 Research News Clinical Updates Publications NeuroInsights Product News search articles Scientists discover neuron-producing stem cells in the membranes covering the brain November 23,
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationInnovative Medicines Initiative
Innovative Medicines Initiative Innovative Medicines Initiative: Joining forces in the healthcare sector The European Union and the pharmaceutical industry have joined forces to make drug R&D processes
More informationKazuhiro Maeta 1,3, Satoko Hattori 2, Junji Ikutomo 1, Hironori Edamatsu 1, Shymaa E. Bilasy 1,4, Tsuyoshi Miyakawa 2 and Tohru Kataoka 1*
Maeta et al. Molecular Brain (2018) 11:27 https://doi.org/10.1186/s13041-018-0370-y RESEARCH Comprehensive behavioral analysis of mice deficient in Rapgef2 and Rapgef6, a subfamily of guanine nucleotide
More informationModel-Based Qualification of Biomarkers. Klaus Romero, MD MS FCP Director of Clinical Pharmacology and Quantitative Medicine
Model-Based Qualification of Biomarkers Klaus Romero, MD MS FCP Director of Clinical Pharmacology and Quantitative Medicine Critical Path Initiative (CPI) Critical Path Institute (C-Path) Independent 501(c)3
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More informationEpidemiology in the era of digital data. Andrew Roddam September 2017
Epidemiology in the era of digital data Andrew Roddam September 2017 There are four big decisions in making medicines Molecule Target Clinical biological experiment Demonstration of clinical effect and
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationThe Innovative Medicines Initiative
The Innovative Medicines Initiative Innovative funding for biotechs & SMEs in Europe Pierre Meulien, IMI Executive Director BIO-Europe Conference, Copenhagen 06.11.2018 IMI Europe s partnership for health
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Coordinating approaches to research across the globe Adriana Maggi JPND Vice-Chair Rome Dec 15, 2017 A European Research Area and beyond We
More informationInduced Stem Cells in Research and Therapy of Neuropsychiatric Disorders
Berlin-Brandenburg Center for Regenerative Therapies Induced Stem Cells in Research and Therapy of Neuropsychiatric Disorders Josef Priller Department of Neuropsychiatry Laboratory of Molecular Psychiatry
More informationHST MEMP TQE Concentration Areas ~ Approved Subjects Grid
HST MEMP TQE Concentration Areas ~ Approved Subjects Grid Aeronautics and Astronautics Biological Engineering Brain and Cognitive Sciences Chemical Engineering 2.080J; 2.183J; choose BOTH choose ONE choose
More informationTopic: Development and validation of translational platforms in support of synaptopathy drug discovery
Topic: Development and validation of translational platforms in support of synaptopathy drug discovery All information regarding future IMI Call topics is indicative and subject to change. Final information
More informationThe Mouse as Animal Model
The Mouse as Animal Model 1. Genetic manipulation is possible Transgenic mice Gene targeted mice 2. Three month generation time 3. Behavioural test are available 4. Physiology is well established Reverse
More informationWebinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
More informationEU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD
EU perspective: European procedure for Qualification of novel methodologies for medicine development Elmer Schabel MD Nothing to disclose See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ex
More informationBD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease Impact of Big Data Analytics on Healthcare 4-5 October 2017, Luxembourg Dr
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationNational adapted qualification concept for the Job Coach for persons with disabilities
National adapted qualification concept for the Job Coach for persons with disabilities Dillenburger, K., & McKerr, L. (2017). National adapted qualification concept for the Job Coach for persons with disabilities.
More informationNEUROSCIENCE AND NEUROLOGICAL DISORDERS
SPONSORSHIP & EXHIBITION 2019 Neuroscience Congress 2019 Theme: Collaborating the Building Blocks of Neuroscience and Psychiatric Experts 2 nd International Conference on NEUROSCIENCE AND NEUROLOGICAL
More informationAnnual statistical report for animals used in Ireland under scientific animal protection legislation
Annual statistical report for animals used in Ireland under scientific animal protection legislation - 2017 15 NOV 2018 Table of Contents 1 INTRODUCTION... 3 2 SUMMARY... 5 3 RESULTS... 6 3.1 Species and
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationLETTER OF INTENT Early Phase Clinical Trials 2018
LETTER OF INTENT Early Phase Clinical Trials 2018 Applications are being accepted on a rolling basis. This Letter of Intent is an example only. Do not complete this paper application. Please submit the
More informationIntroducing the Department of Life Sciences
Introducing the Department of Life Sciences Life Sciences is a discipline that aims at a fundamental understanding of life phenomena by exploring complex and mysterious structures and funct ions of living
More informationIndustry Case Study: Expanded Access at Ultragenyx
Industry Case Study: Expanded Access at Ultragenyx Hank Mansbach, MD VP, Medical Affairs September 13, 2016 www.ultragenyx.com Introduction to Ultragenyx A clinical-stage biopharmaceutical company based
More informationThe Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
More informationBioXplain The Alliance for Integrative Biology
The Alliance for Integrative Biology The First Open Platform for Iterative, Predictive and Integrative Biology Manuel GEA Co-founder & CEO Bio-Modeling Systems BioXplain 2009 Pharma R&D critical challenge
More informationInnovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011
Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research Krakow Biotechnology congress - 13 October 2011 Fatiha Sadallah IMI Scientific Manager What is the Innovative Medicines
More informationINTRODUCTION TO MOLECULAR GENETICS. Andrew McQuillin Molecular Psychiatry Laboratory UCL Division of Psychiatry 22 Sept 2017
INTRODUCTION TO MOLECULAR GENETICS Andrew McQuillin Molecular Psychiatry Laboratory UCL Division of Psychiatry 22 Sept 2017 Learning Objectives Understand: The distinction between Quantitative Genetic
More informationInnovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions
Innovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions Oslo EAFP 19 June 2009 1200 km 2 2 Billion EURO 1 Billion Euro 1 Billion Euro Public Private Partnership
More informationand behavior B. Hans Frossberg, PhD I. The Journal The Institutions A. Rochellys Diaz Heijtz, PhD C. Sven Petterson, MD
Normal gut microbiota modulates brain development and behavior Rollchellys Diaz Heijitz, Shugui Wang, Farhana Anuar, Yu Quian, Britta Bjorkholm, Annika Samuelsson, Martin L Hibberd, Hans Forssberg, and
More informationGeneration and Application of Genetically Modified Mouse Models of Human Disease.
Generation and Application of Genetically Modified Mouse Models of Human Disease. Nina Balthasar RCUK and BHF Research Fellow Department of Physiology and Pharmacology University of Bristol The Plan Techniques
More informationNEUROSCIENCE. Neurodegenerative Disease Research: Steps to a Successful Clinical Trial ABSTRACT
WHITE PAPER PRESENTED BY PREMIER RESEARCH Neurodegenerative Disease Research: Steps to a Successful Clinical Trial ABSTRACT Neurodegenerative disorders present some of the biggest challenges in planning
More informationJ ove VIDEO JOURNAL CATALOG A CATALYST FOR SCIENTIFIC RESEARCH AND EDUCATION
J ove VIDEO JOURNAL CATALOG A CATALYST FOR SCIENTIFIC RESEARCH AND EDUCATION J ove VIDEO JOURNAL The first scientific video journal dedicated to advancing science by increasing reproducibility and efficient
More information